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ABSTRACT
Objectives: Estimate the epidermal growth factor receptor (EGFR) mutation 
prevalence in all non-small cell lung cancer (NSCLC) patients and patient subgroups.
Results: A total of 456 studies were included, reporting 30,466 patients with 
EGFR mutation among 115,815 NSCLC patients. The overall pooled prevalence for 
EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% 
CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe. The 
pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% 
vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or 
current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with 
adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 
4.1, 95% CI: 3.6 to 4.8).
Materials and Methods: PubMed, EMBASE, and the Cochrane Library were 
searched to June 2013. Eligible studies reported EGFR mutation prevalence and the 
association with at least one of the following factors: gender, smoking status and 
histology. Random-effects models were used to pool EGFR mutation prevalence data.
Conclusion: This study provides the exact prevalence of EGFR mutations in 
different countries and NSCLC patient subgroups.
INTRODUCTION
Lung cancer is the most common cause of cancer 
death, claiming 1.59 million lives in 2012 worldwide 
[1]. Non-small cell lung cancer (NSCLC) accounts for 
approximately 85% of all lung cancers and chemotherapy 
is one of the key components in the treatment protocol [2]. 
Although there is strong evidence to show that standard 
chemotherapy in addition to best supportive care can prolong 
overall survival and improve the quality of life [3], prognosis 
remains poor, especially in patients with advanced NSCLC. 
The median overall survival and the 5-year survival rate is 
only 1 year and 3.5%, respectively [4].
A large proportion of NSCLC patients have 
sensitizing mutations in exon 19 or 21 (approximately 
45 and 40% of patients, respectively) which activate 
the tyrosine kinase domain in epidermal growth factor 
receptors (EGFR). The discovery of EGFR tyrosine kinase 
inhibitors (TKI) was regarded as a landmark finding in 
the treatment of lung cancer [5–8]. Targeted EGFR-TKI 
first-line treatment of sensitizing EGFR mutations results 
in longer PFS, improved health-related quality of life 
and decreased treatment-related severe side effects when 
compared with those who received standard chemotherapy 
[6, 7, 9–13]. Many clinical guidelines therefore recommend 
that all patients with sensitizing EGFR mutations receive 
first-line treatment with these drugs [14–19], in addition to 
all patients with advanced or metastatic NSCLC [2, 20].
Despite benefits in using EGFR-TKIs for first-line 
therapy in all sensitizing mutations, in resource limited 
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situations, targeted screening may be appropriate [21]. 
Knowledge on the prevalence of EGFR mutations in 
different patient subgroups could therefore inform policy 
and testing strategies. Existing individual studies may not 
be informative for estimating prevalence because of small 
sample sizes in case-series or non-representative sample 
selection. The mutation prevalence reported in whole 
study or sub-group populations also varies dramatically 
in published studies [22–30] and the reported prevalence 
rates are therefore currently inappropriate for applying 
to other populations. In order to obtain a more precise 
estimate of EGFR mutation prevalence in NSCLC patients 
and patient subgroups, we conducted this systematic 
review and meta-analysis.
RESULTS
We identified 6,221 potentially eligible citations, 
of which 456 studies were finally included (Figure 1). 
The majority of included studies were case series 
(56.6%) and cohort studies (33.2%). Sixty-six percent 
of the studies were conducted in Asian countries. The 
median sample size was 103, ranging from 11 to 18,246. 
Median participant age was 63 years, 56.1% were males 
and 57.0% were past or current smokers. Histology was 
reported in 45.0% of studies and 73.3% of patients had 
adenocarcinoma. EGFR exon 19 or 21 mutation was 
assessed in 89.3% of the studies (see Table A.1 for study 
characteristics).
In total, 30,466 patients with an EGFR mutation 
were reported among 115,815 patients with NSCLC. 
The overall pooled prevalence of all EGFR mutations 
and EGFR exon 19 or 21 mutations was 32.3% (95% CI: 
30.9% to 33.7%) and 32.2% (95% CI: 29.6% to 34.8%), 
respectively (Table 1). EGFR mutation prevalence varied 
by study location and ethnicity: Asia had the highest 
prevalence (38.4%, 95% CI: 36.5% to 40.3%) [China: 
38.4% (95% CI: 35.7% to 41.1%); Japan: 36.6% (95% 
CI: 33.2% to 40.0%); Korea 32.4% (95% CI: 28.0% to 
36.8%)], followed by North and South America (24.4%, 
95% CI: 22.1% to 26.8%) and Europe (14.1%, 95% 
CI: 12.7% to 15.5%). The prevalence among different 
ethnicities were similar to study locations, with the 
prevalence of 38.8% (95% CI: 36.8% to 40.8%) in 
Asian populations, 17.4% (95% CI: 15.8% to 18.9%) in 
Caucasians, 17.2% (95% CI: 5.7% to 28.8%) in African-
Americans, and 27.0% (95% CI: 22.6% to 31.4%) in 
mixed populations.
Many study or patient characteristics had little 
influence on EGFR mutation prevalence rates, including 
the disease stage at diagnosis, history of chemotherapy, 
mutation detection methods (post-hoc analysis of methods 
reported in 10+ studies) or year of study publication (post-
hoc analysis) (Table A.2 for post-hoc analysis).
Table 2 provides associations between of EGFR 
mutation prevalence and gender, smoking status, and 
tumor histology in Caucasian and Asian populations. 
Overall, prevalence was higher in females (females vs. 
males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9) 
and the ORs did not differ significantly by ethnicity: 
Caucasian females vs. males OR 2.7, 95% CI 2.3 to 3.3; 
Asian females vs. males OR 2.8, 95% CI 2.6 to 3.1. The 
prevalence was also higher overall in non-smokers (non-
smoker vs. past or current smoker: 49.3% vs. 21.5%; OR: 
3.7, 95% CI: 3.4 to 4.0). Among non-smokers, as compared 
to past or current smokers, the mutation prevalence in 
Caucasians was greater than in Asians: Caucasian non-
smokers vs. past or current smokers 39.8% vs. 10.8%; 
OR: 5.2, 95% CI: 4.4 to 6.3; Asian non-smokers vs. past 
or current smokers 52.2% vs. 26.3%; OR: 3.3, 95% CI: 2.9 
to 3.6. NSCLC patients with adenocarcinoma were also far 
more likely to carry the EGFR mutation (adenocarcinoma 
vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% 
CI: 3.6 to 4.8) in overall participants. This observation was 
more striking in the Asian population (adenocarcinoma vs. 
non-adenocarcinoma: 44.7% vs. 12.5%; OR: 5.3, 95% CI: 
4.4 to 6.4) than the Caucasian population (adenocarcinoma 
vs. non-adenocarcinoma: 19.7% vs. 9.6%; OR: 2.2, 95% 
CI: 1.7 to 2.7). The prevalence of EGFR mutation was not 
different in patients diagnosed at different NSCLC stages 
and by chemotherapy use history.
The prevalence trends in different patient groups 
remained when countries with at least of 50 studies 
were assessed separately (China, Japan, Korea and U.S) 
(Table A.3 to A.6). Notable exceptions included a very 
low prevalence (3.3%, 95% CI: 2.4% to 4.1%) among 
patients with non-adenocarcinoma patients in Japan (Table 
A.4) and the higher prevalence for those who previously 
received chemotherapy in Japan (45.3%, 95% CI: 37.7% 
to 52.8%) and Korea (34.8%, 95% CI: 18.4% to 51.2%) 
(Tables A.4 and A.5).
DISCUSSION
In this study, we found that approximately one-
third of NSCLC patients harbor an EGFR mutation. 
Patients who are Asian, female, non-smokers, and have 
adenocarcinoma are more likely to harbor an EGFR 
mutation, which is consistent with previous studies [23, 
29, 31–33].
Some previous systematic reviews were published 
reporting the prevalence of EGFR mutation in patients 
with non-small cell lung cancer [34–38]. These previously 
published work focused on patient subgroups such as 
smokers, adenocarcinomas or studies only in Chinese 
population. Moreover, all these previous reviews did not 
employ meta-analysis method to pool the prevalence from 
original studies. Despite of these difference, the pooled 
prevalence estimates we generated were similar to these 
smaller systematic reviews. The overall pooled prevalence 
in our study is similar to some existing large individual 
studies, though there is considerable variation among 
Oncotarget78987www.impactjournals.com/oncotarget
countries and individual studies may not be relied upon 
for accurate prevalence rates [39–41]. Individual study 
divergence from the pooled estimates likely reflects the 
patient characteristics within studies. EGFR mutation 
prevalence is clearly influenced by these characteristics 
and thus, this large review of whole populations and 
subgroups provides the best evidence for EGFR mutation 
prevalence [42, 43].
Recent clinical guidelines from the American 
Society of Clinical Oncology (ASCO) and the National 
Comprehensive Cancer Network (NCCN) recommend 
all patients with advanced or metastatic non-squamous 
NSCLC to receive EGFR mutation testing [2, 44]. A cost-
effectiveness analysis also supports mutation testing vs. no 
testing for eligibility of second-line gefitinib treatment, after 
the failure of platinum-containing doublet [45]. However, 
Figure 1: The flow chart of study selection. This figure provides detailed information for the study inclusion and exclusion.
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Table 1: The pooled prevalence of EGFR mutation in different NSCLC patient subgroups
Group variables No. of studies
Mutation prevalence, 
% (95%CI)
Tests of heterogeneity
P I2(%)
All studies 456 32.3(30.9 to 33.7) <0.001 97.3
Exon mutation location
 Exon 19 343 16.7(15.8 to 17.5) <0.001 93.2
 Exon 21 330 12.3(11.6 to 13.0) <0.001 92.7
 Exon 19 or 21 95 32.2(29.6 to 34.8) <0.001 95.5
 Exon 18 90 1.2(1.0 to 1.4) <0.001 48.6
 Exon 20 93 1.7(1.4 to 2.0) <0.001 64.2
Study location (continent)*
 Asia 304 38.4(36.5 to 40.3) <0.001 95.6
 America (North and South) 81 24.4(22.1 to 26.8) <0.001 96.8
 Europe 62 14.1(12.7 to 15.5) <0.001 87.3
Study location (country)
 Japan 107 36.6(33.2 to 40.0) <0.001 96.4
 China 104 38.4(35.7 to 41.1) <0.001 93.0
 Korea 48 32.4(28.0 to 36.8) <0.001 94.8
 U.S. 68 23.9(21.3 to 26.5) <0.001 96.6
Ethnicity
 Caucasian 96 17.4(15.8 to 18.9) <0.001 92.0
 Asian 301 38.8(36.8 to 40.8) <0.001 95.8
 African-American 5 17.2(5.7 to 28.8) <0.001 89.0
 Mixed 32 27.0(22.6 to 31.4) <0.001 96.9
 Unclear 22 19.3(16.4 to 22.2) <0.001 94.3
Gender
 Male 322 24.0(22.5 to 25.4) <0.001 94.2
 Female 331 43.7(41.5 to 45.9) <0.001 94.8
Smoking status
 Non-smoker 284 49.3(47.2 to 51.4) <0.001 91.5
 Past or current smoker 280 21.5(20.2 to 22.7) <0.001 92.2
Histology
 Adenocarcinoma 307 38.0(36.0 to 40.1) <0.001 96.6
 Non-adenocarcinoma 203 11.7(10.6 to 12.7) <0.001 83.6
Stage
 Stage I 73 34.0(28.9 to 39.1) <0.001 97.4
 Stage II 55 29.9(25.0 to 34.7) <0.001 84.9
 Stage III 85 33.8(29.8 to 37.8) <0.001 89.0
 Stage IV 68 37.5(33.2 to 41.7) <0.001 93.3
Chemotherapy
 Chemotherapy 42 33.8(27.1 to 40.5) <0.001 97.8
 No chemotherapy 74 33.2(29.3 to 37.1) <0.001 96.7
Legend: This table provides pooled prevalence and results from heterogeneity test of EGFR mutation in all eligible studies 
and different subgroups
*Europe includes countries of the European Union and Norway, Switzerland, and Turkey; America includes Canada, 
the United States, Argentina, Brazil, Colombia, Mexico, and Peru; Asia includes China, East Asia, India, Japan, Korea, 
Malaysia, Singapore, Taiwan, and Thailand.
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this may require substantial resources and effort and at 
present, the cost of EGFR mutation testing in some countries 
is met by patients’ out-of-pocket expenses or from research 
funds, and can vary from U.S.$ 150 to several hundred 
U.S.$ [46]. Although non-invasive genetic testing methods 
exist [47], mutation detection using tumor tissues is still 
the gold standard for EGFR mutation testing. Such barriers 
prevent the widespread use of EGFR mutation testing 
and testing rates likely reflect the level of health service 
development and insurance coverage. EGFR mutation 
testing rates in NSCLC vary considerably among countries 
with approximately 9.6% in Chinese metropolitan areas in 
2010 [48] and approximately 39.5% and 53.9% of patients 
in Korea and Japan, respectively [49, 50]. Where full 
coverage of screening is not available or possible, providers 
may target the patient groups identified in this review who 
are more likely to harbor mutations (e.g. 51.5% of Asian 
females, 52.2% of Asian smokers, 44.7% of Asian patients 
with adenocarcinoma, and 39.8% of Caucasian non-smokers 
harbor an EGFR mutation). Although EGFR mutation 
prevalence in some populations is relatively low at about 
10% (e.g. 10.1% in Caucasian males and 12.5% in Asian 
patients with non-adenocarcinoma) screening must still be 
provided and only be targeted in resource limited settings. 
Given the fact that the efficacy of standard chemotherapy for 
patients with NSCLC remains limited, universal testing for 
EGFR mutation may improve overall prognosis through the 
early use of first-line EGFR-TKI treatment.
A major strength of this work is the large number 
and range of studies included to estimate the prevalence 
of EGFR mutation in different NSCLC patient groups. 
These estimates can serve as the reference for the future 
research or policy making. However, several limitations 
of our study need to be mentioned. Firstly, since patients 
with higher likelihood of harboring an EGFR mutation 
are more likely to be tested, the overall prevalence 
Table 2: The association of EGFR mutation with gender, smoking status, and tumor histology in Caucasian and 
Asian populations
Group variables
No. of 
studies
Mutation 
prevalence, 
95%CI, (%)
Tests of heterogeneity
OR (95% CI)
P I2(%)
Caucasian population
Gender
 Female 66 25.0(22.4 to 27.7) <0.001 87.2 2.7(2.3 to 3.3)
 Male 62 10.1(8.6 to 11.5) <0.001 86.1 1.0
Smoking status
 Non-smoker 56 39.8(36.3 to 43.2) <0.001 76.8 5.2(4.4 to 6.3)
 Past or current smoker 56 10.8(9.4 to 12.2) <0.001 82.9 1.0
Histology
 Adenocarcinoma 61 19.7(17.5 to 21.8) <0.001 89.6 2.2(1.7 to 2.7)
 Non-adenocarcinoma 40 9.6(7.6 to 11.5) <0.001 84.1 1.0
Asian Population
Gender
 Female 231 51.1(48.9 to 53.3) <0.001 88.0 2.8(2.6 to 3.1)
 Male 228 28.7(26.7 to 30.6) <0.001 92.6 1.0
Smoking status
 Non-smoker 197 52.2(49.7 to 54.7) <0.001 91.5 3.3(2.9 to 3.6)
 Past or current smoker 194 26.3(24.3 to 28.2) <0.001 91.7 1.0
Histology
 Adenocarcinoma 214 44.7(42.4 to 47.0) <0.001 93.8 5.3(4.4 to 6.4)
 Non-adenocarcinoma 144 12.5(11.1 to 13.9) <0.001 84.0 1.0
Legend: This table provides pooled prevalence and results from heterogeneity test of EGFR mutation, and the pooled 
within-study ORs for the association between subgroup variables and EGFR mutation, in Caucasian populations and Asian 
populations respectively.
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may be overestimated. However, detailed recruitment 
information was not provided in many studies so we could 
not assess the influence of selection bias. Secondly, lack 
of relevant studies prevented us from further exploring 
the prevalence of EGFR mutation in some patient 
subgroups, such as Asian female non-smokers and Asian 
female adenocarcinoma patients. Thirdly, significant 
heterogeneity was found among included studies in 
almost all the analyses, which seems common in meta-
analysis of single arm studies. The substantial difference 
in patient characteristics, clinical settings, and research 
methodologies among eligible studies may contribute to 
the high level of heterogeneity. Unfortunately, without 
individual patient data it is not possible to further sub-
divide prevalence estimates for precise patient groups 
such as women in the U.S. who are non-smokers and have 
adenocarcinoma. Despite noted limitations, we believe that 
this comprehensive synthesis of existing available studies 
provides valuable estimates of EGFR mutation prevalence.
This systematic review and meta-analysis estimates 
the prevalence of EGFR mutations in NSCLC patient 
subgroups. EGFR mutation prevalence estimates in these 
subgroups can inform policy makers of those patients who 
are more likely to benefit from EGFR-TKI treatment.
MATERIALS AND METHODS
Data sources and search strategy
We performed a comprehensive literature search 
in PubMed, EMBASE, and Cochrane Library from 
their respective inception to June 2013, with different 
combinations of the following keywords: “EGFR”, “lung 
cancer”, and “mutation”. The literature search was restricted 
to human studies. No language restriction was applied. We 
manually checked reference lists of the included studies and 
relevant reviews to identify additional studies. Details of the 
search strategy are summarized in Table A.7.
Study selection
Studies reporting the prevalence of EGFR mutation 
and odds ratio (OR) to estimate the association of EGFR 
mutation with at least one of the following factors 
(gender, smoking status, and histology) in patients 
with NSCLC were considered eligible. For duplicate 
publications, we selected the most recent and complete 
version of publications. Two reviewers (WKF and 
YJQ) independently assessed the study eligibility. Any 
discrepancies were resolved by consensus or by consulting 
with a third reviewer (MC).
Data extraction
Data extraction was performed independently by 
two reviewers (WKF and YJQ). Disagreements were 
resolved by discussion between the two. If no agreement 
was reached, then a third researcher (MC) was invited 
to resolve the disagreement. The following data were 
collected from each study using a predefined data 
extraction form: study characteristics (such as the first 
author’s name, year of publication, study location, study 
design, and sample size), patient characteristics (such 
as proportion of females, proportion of non-smokers, 
and proportion of adenocarcinoma), and the prevalence 
of EGFR mutation (such as the number of patients with 
EGFR mutation and OR for association of EGFR mutation 
with gender, smoking status, and histology).
Outcome measure and subgroup variables
We defined the primary outcome of interest in this 
systematic review as EGFR mutation. The prevalence of 
EGFR mutation was defined as the proportion of patients 
with EGFR mutation among patients who received the 
mutation testing. Study location was determined using 
the place where the patients were recruited in the study. 
If the authors did not describe the patient recruitment, the 
affiliation address of the corresponding author was used 
to identify the study location. Population ethnicity was 
divided into Caucasian, Asian, African-American, and 
mixed ethnicities. Ethnicity classification was based on 
the information in the original publication or the principle 
ethnicity of each country, where the detailed information 
was not reported (e.g. Italy = Caucasian, Japan = Asian). 
Similarly, the classifications of smoking status, tumor 
histology, tumor stage, and previous use of chemotherapy 
were defined according to the information in original 
publications.
Data analysis
We conducted meta-analysis to pool the prevalence 
of EGFR mutation in different NSCLC patient groups. 
Subgroup analyses were performed according to the 
following factors: EGFR exons (exon 19, 21 or both, and 
the others), study locations (at least 50 studies in each 
location), ethnicity, gender, smoking status (non-smoker or 
past or current smoker), tumor histology (adenocarcinoma 
or non-adenocarcinoma), tumor stage, and previous use 
of chemotherapy. The within-study OR was combined to 
estimate the association of EGFR mutation with gender, 
smoking status, and tumor histology. Post-hoc subgroup 
analysis was conducted according to the detection 
methods of EGFR mutation, types of samples used in the 
detection, and the publication year of the study. Given the 
diverse nature of studies and the likely heterogeneity, we 
applied random-effects models to carry out meta-analysis 
by the Der-Simonian Laird method [51]. The statistical 
heterogeneity among the studies was assessed by the 
Cochran’s Q-test and the I2 statistic. A P value ≤ 0.10 for 
the Cochran’s Q-test or an I2 ≥ 50% was suggestive of 
significant among-study heterogeneity. We used Stata 
12.0 (StataCorp, College Station, TX) to conduct all the 
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analyses with a two-tailed significance level of 0.05 except 
in the assessment of heterogeneity (α = 0.10).
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